NATCO Pharma Limited

NATCOPHARM

INE987B01026

Pharmaceuticals

Delayed NSE India S.E. Other stock markets 12:02:41 2024-05-22 am EDT			5-day change	1st Jan Change
1,001 ^INR	+0.19%		+1.92%	+23.47%

May. 08	AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents	MT
May. 08	AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents	MT

Natco Pharma Limited Announces Redesignation of M. Adinarayana as Company Secretary & Vice President (Legal & Corporate Affairs)

June 20, 2013 at 09:02 am EDT

Natco Pharma Limited announced that the designation of Mr. M. Adinarayana, Compliance Officer has been redesignated as Company Secretary & Vice President (Legal & Corporate Affairs).

Latest news about NATCO Pharma Limited

AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents	May. 08	MT
AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents	May. 08	MT
AstraZeneca, Merck Sue Over Alleged Cancer Drug Patents Infringement	May. 08	MT
Natco Pharma Gets US FDA Warning Letter after Inspection of Kothur, India Unit	Apr. 09	MT
NATCO Pharma Limited Announces Board Appointments	Mar. 27	CI
INDIA STOCKS-Indian shares erase early gains, weighed down by IT stocks	Feb. 18	RE
NATCO Pharma Limited Revises Earnings Guidance for the Fiscal Year 2024	Feb. 15	CI
Transcript : NATCO Pharma Limited, Q3 2024 Earnings Call, Feb 15, 2024	Feb. 15
Corporate Action-Board Approves Third Interim Dividend for the Financial Year 2023-24, Payable on 4 March 2024	Feb. 14	CI
NATCO Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 14	CI
Cellogen Therapeutics announced that it has received $2 million in funding from NATCO Pharma Limited	Jan. 16	CI
Floods Disrupt Operations of Natco Pharma's Plant in Tamil Nadu, India	Dec. 07	MT
Transcript : NATCO Pharma Limited, Q2 2024 Earnings Call, Nov 15, 2023	Nov. 15
Natco Pharma's Consolidated Profit Soars in Fiscal Q2, Declares Second Interim Dividend	Nov. 14	MT
NATCO Pharma Limited Declares Second Interim Dividend for the Financial Year 2023-24, Payable on 1 December, 2023	Nov. 14	CI
NATCO Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 14	CI
US FDA Clears Natco Pharma's Pharmacovigilance Department in Hyderabad, India	Nov. 02	MT
Transcript : NATCO Pharma Limited - Shareholder/Analyst Call	23-09-29
Redcliffe Hygiene Private Limited announced that it has received INR 248 million in funding from Rainmatter, Alkemi Growth Capital LLP, NATCO Pharma Limited	23-09-11	CI
Indian Equities End Higher for Sixth Straight Day, Buoyed by Banking, Public Sector Enterprises	23-09-08	MT
Natco Pharma, Three Others Face Antitrust Violation Raps in US; Natco Pharma Shares Drop 3%	23-09-08	MT
Bristol Myers accused of illegal tactics to keep Pomalyst monopoly in lawsuit	23-09-06	RE
Indian shares set to open flat on caution ahead of GDP data	23-08-30	RE
Transcript : NATCO Pharma Limited, Q1 2024 Earnings Call, Aug 10, 2023	23-08-10
Natco Pharma to Form UK Arm	23-08-09	MT

Natco Pharma Limited is an India-based vertically integrated pharmaceutical company with focus on research and development. The Company is engaged in in the development, manufacturing and commercialization of complex pharmaceuticals that target specific therapeutic areas. It specializes in catering to niche markets and offering solutions to address complex medical needs. It owns nine manufacturing facilities across India and two research centers in Telangana. The Companyâs segment includes Pharmaceuticals and Agro chemicals. Its Pharmaceuticals segment is engaged in manufacturing and selling of bulk drugs, finished dosage formulations and related services. Its Agro Chemicals is engaged in manufacturing and selling of agro chemical. It manufactures active pharmaceutical ingredients products which are primarily used for captive consumption in its FDF products and are also sold to customers for various international markets such as Brazil, Europe, and United States of America.

Sector

Pharmaceuticals

Calendar

2024-05-26 - Q4 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for NATCO Pharma Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

999.2 INR

Average target price

975.4 INR

Spread / Average Target

-2.39%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NATCO PHARMA LIMITED	+23.47%	2.15B
ELI LILLY AND COMPANY	+37.78%	705B
NOVO NORDISK A/S	+32.82%	583B
JOHNSON & JOHNSON	-3.51%	364B
MERCK & CO., INC.	+19.94%	332B
ABBVIE INC.	+5.14%	291B
ASTRAZENECA PLC	+16.64%	238B
ROCHE HOLDING AG	-4.13%	210B
NOVARTIS AG	+10.63%	209B
AMGEN INC.	+9.32%	169B

Other Pharmaceuticals